Outcome of Primary Childhood Central Nervous System Tumors: Results from a Single Center in Iran

Kh. Arjmandi Rafsanjani; Gr. Bahoush; F. Nikpoor; P. Vossough

doi:10.1055/s-0032-1324398

Neuropediatrics, Table of Contents

Neuropediatrics 2012; 43(05): 232-237
DOI: 10.1055/s-0032-1324398

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Outcome of Primary Childhood Central Nervous System Tumors: Results from a Single Center in Iran

Kh. Arjmandi Rafsanjani

¹Department of Pediatrics, Pediatric Hemato and Oncology, Ali-Asghar Children's Hospital, Tehran University of Medical Sciences, SIOP Member, Tehran, Islamic Republic of Iran

,

Gr. Bahoush

²Department of Pediatrics, Pediatric Hemato and Oncologist, Onco-pathology Research Center, Ali-Asghar Children's Hospital, Tehran University of Medical Sciences, and SIOP Member, Tehran, Islamic Republic of Iran

,

F. Nikpoor

³Ali-Asghar Children's Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran

,

P. Vossough

⁴Department of Pediatrics, Pediatric Hemato and Oncologist, Ali-Asghar Children's Hospital, Tehran University of Medical Sciences, SIOP Member, Tehran, Islamic Republic of Iran

› Author Affiliations

Abstract

Background Childhood primary central nervous system (CNS) malignancies are one of the most important concerns in pediatric oncology.

Material In this historical cohort, 82 patients treated in Ali-Asghar Children's Hospital between 1996 and 2005 were evaluated for age, gender, type of treatment, tumor pathology, and survival.

Results The records of 38 female (46.3%) and 44 male (53.7%) patients were included. The mean age was 6.8 ± 3.39 years (6 months to 14 years); the frequency of medulloblastoma was significantly more than others (p = 0.012). Complete resection, radiotherapy, and chemotherapy were done in 47.5, 82.9, and 97.56%, respectively. Estimated 5 years overall and event-free survivals (EFSs) were approximately 68.5 and 35%, respectively. The patients with complete resected tumors had significantly better outcome (p = 0.013). Also, low-grade versus high-grade astrocytoma was significantly a better outcome (p = 0.01).

Conclusion The poor EFS with consideration of high number of progressive disease among our patients (50% unresectable tumor) suggests that children in Iran with CNS tumors had high quality of care but availability of advanced treatment protocol and sharing of cooperative trial study is essential for survival improvement. In addition to use more advanced methods and equipments of radiotherapy and chemotherapeutic drugs, we should seriously consider development of better surgical techniques to increase the rate of complete resection of malignant CNS tumors.

Keywords

malignant central nervous system tumors - survival - pediatrics

Full Text

References

References
1 Bleyer WA. Epidemiologic impact of children with brain tumors. Childs Nerv Syst 1999; 15 (11-12) 758-763
2 Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro-oncol 1999; 1 (3) 205-211
3 Kaatsch P, Rickert CH, Kühl J, Schüz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer 2001; 92 (12) 3155-3164
4 Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001; 17 (9) 503-511
5 Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M ; EUROCARE Working Group. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23 (16) 3742-3751
6 Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998; 88 (1) 1-10
7 Gloeckler Ries LA, Miller BA, Hankey BF , et al, eds. SEER cancer statistic review: 1973–1991, table and graphs. NIH Pub. No. 94–2789. Bethesda, MD: National Cancer Institutes of Health; 1994
8 Lashford LS, Thiesse P, Jouvet A , et al; A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002; 20 (24) 4684-4691
9 Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999; 91 (12) 1051-1058
10 Louis DN, Ohgaki H, Wiestler OD , et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (2) 97-109
11 Pizzo PA, Poplack DG. Principle and Practice of Pediatric Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005
12 Smith MA, Freidlin B, Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst 1998; 90 (17) 1269-1277
13 Stiller CA. Population based survival rates for childhood cancer in Britain, 1980-91. BMJ 1994; 309 (6969) 1612-1616
14 Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-oncol 1999; 1 (1) 14-25
15 Farinotti M, Ferrarini M, Solari A, Filippini G. Incidence and survival of childhood CNS tumours in the Region of Lombardy, Italy. Brain 1998; 121 (Pt 8) 1429-1436
16 Parkin DM, Stiller CA, Draper GJ , et al, eds. International Incidence of Childhood Cancer. IARC Scientific Publications No. 87. Lyon: International Agency for Research on Cancer; 1988
17 Berrino F, Capocaccia R, Hakulinen T, Sant M, Verdecchia A. Survival of cancer patients in Europe. The EUROCARE Study. IARC Scientific Publications, No. 132. Lyon: International Agency for Research on Cancer; 1995
18 Magnani C, Pastore G ; ITACARE Working Group. Survival of childhood cancer patients in Italy, 1978-1989. Tumori 1997; 83 (1) 426-489
19 Sposto R, Ertel IJ, Jenkin RD , et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 1989; 7 (2) 165-177
20 Wolff JE, Gnekow AK, Kortmann RD , et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 2002; 94 (1) 264-271
21 Desai KI, Nadkarni TD, Muzumdar DP, Goel A. Prognostic factors for cerebellar astrocytomas in children: a study of 102 cases. Pediatr Neurosurg 2001; 35 (6) 311-317
22 Fisher PG, Tihan T, Goldthwaite PT , et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008; 51 (2) 245-250
23 Pencalet P, Maixner W, Sainte-Rose C , et al. Benign cerebellar astrocytomas in children. J Neurosurg 1999; 90 (2) 265-273
24 Pollack IF, Claassen D, al-Shboul Q, Janosky JE, Deutsch M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 1995; 82 (4) 536-547
25 Sievert AJ, Fisher MJ. Pediatric Low-Grade Gliomas. Available from: jcn.sagepub.com at Yale University Library on June 22, 2011, Accessed: 10 Nov 2011
26 Smoots DW, Geyer JR, Lieberman DM, Berger MS. Predicting disease progression in childhood cerebellar astrocytoma. Childs Nerv Syst 1998; 14 (11) 636-648